Type I topoisomerase
Type I topoisomerase is an enzyme that plays a crucial role in the DNA replication and transcription processes by altering the supercoiling of DNA. It achieves this by creating a transient single-strand break in the DNA, allowing the DNA to unwind or rewind, and then resealing the break. This action is essential for relieving the torsional strain that builds up ahead of the replication fork and during transcription.
Function[edit]
Type I topoisomerases are responsible for cutting one strand of a DNA double helix, allowing it to rotate around the uncut strand, and then rejoining the cut strand. This process is ATP-independent, distinguishing it from Type II topoisomerases, which require ATP to function. The enzyme's ability to relax supercoiled DNA is vital for maintaining the proper structure and function of the genome.
Mechanism[edit]
The mechanism of Type I topoisomerase involves several steps:
- Cleavage: The enzyme binds to the DNA and cleaves one of the strands, forming a covalent bond between the enzyme and the DNA.
- Strand Passage: The uncut strand is passed through the break, allowing the DNA to relax.
- Religation: The enzyme reseals the break, restoring the integrity of the DNA.
This process is facilitated by a tyrosine residue in the active site of the enzyme, which forms a transient covalent bond with the DNA.
Types[edit]
There are two main subtypes of Type I topoisomerases:
- Type IA topoisomerases: These enzymes relax negatively supercoiled DNA and are found in both prokaryotes and eukaryotes.
- Type IB topoisomerases: These enzymes can relax both positive and negative supercoils and are primarily found in eukaryotes.
Biological Importance[edit]
Type I topoisomerases are essential for various cellular processes, including DNA replication, transcription, and chromosome segregation. They help prevent DNA tangling and breakage, which can lead to genomic instability and mutations.
Clinical Significance[edit]
Inhibitors of Type I topoisomerases, such as camptothecin and its derivatives, are used as anticancer agents. These drugs stabilize the transient DNA-topoisomerase complex, preventing the religation step and leading to DNA damage and cell death.
Images[edit]




Related pages[edit]
References[edit]
- Wang, J.C. (1996). "DNA topoisomerases." Annual Review of Biochemistry, 65, 635-692.
- Champoux, J.J. (2001). "DNA topoisomerases: Structure, function, and mechanism." Annual Review of Biochemistry, 70, 369-413.
-
Type I topoisomerase structure
-
Type I topoisomerase
-
Topoisomerase IB active site
-
Topoisomerase IB active site
Medical Disclaimer: WikiMD is for informational purposes only and is not a substitute for professional medical advice. Content may be inaccurate or outdated and should not be used for diagnosis or treatment. Always consult your healthcare provider for medical decisions. Verify information with trusted sources such as CDC.gov and NIH.gov. By using this site, you agree that WikiMD is not liable for any outcomes related to its content. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates, categories Wikipedia, licensed under CC BY SA or similar.
Translate this page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian